Daily close, T-120 (10/11/24) through T+5. Run-up high $2.41 on 3/17/25, low $1.43 on 11/1/24 (T-120 to T-1). FDA decision 3/28/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 14, 2025, 14 days before the decision date, at-the-money options priced a move of ±71.6% through Apr 17, 2025 (the first listed expiry after the decision; ATM implied volatility 285%). The stock closed -60.9% at the first close across the decision and -66.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Not in this review cycle. On March 28, 2025 the FDA issued a Complete Response Letter, declining to approve the application for source-verified in its current form. A CRL is not final; the primary source is linked on this page.
How did MIST stock react to the FDA decision?
On the decision day MIST moved -60.9%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.